ClinicalTrials.gov studies | All (752) | < 2008 (254) | 2008–2015 (498) | |||
---|---|---|---|---|---|---|
N | % | N | % | N | % | |
Study phase | ||||||
0 | 3 | 0.4 | – | – | 3 | 0.6 |
I | 186 | 24.7 | 67 | 26.4 | 119 | 23.9 |
I-II | 54 | 7.2 | 21 | 8.3 | 33 | 6.6 |
II | 313 | 41.6 | 114 | 44.9 | 199 | 40.0 |
II-III | 6 | 0.8 | 2 | 0.8 | 4 | 0.8 |
III | 67 | 8.9 | 21 | 8.3 | 46 | 9.2 |
IV | 7 | 0.9 | 2 | 0.8 | 5 | 1.0 |
Observational | 71 | 9.4 | 18 | 7.1 | 53 | 10.6 |
Missing | 45 | 6.0 | 9 | 3.5 | 36 | 7.2 |
Center | ||||||
Multicenter | 393 | 52.3 | 106 | 41.7 | 287 | 57.6 |
Single-center | 208 | 27.7 | 76 | 29.9 | 132 | 26.5 |
Missing | 151 | 20.1 | 72 | 28.4 | 79 | 15.9 |
Countrya | ||||||
America | 489 | 65.0 | 195 | 76.8 | 294 | 59.0 |
Europe | 114 | 15.2 | 25 | 9.8 | 89 | 17.9 |
International | 99 | 13.1 | 17 | 6.7 | 82 | 16.5 |
Asia | 21 | 2.8 | 4 | 1.6 | 17 | 3.4 |
Oceania | 3 | 0.4 | – | – | 3 | 0.6 |
Study purposea | ||||||
Treatment | 612 | 81.4 | 213 | 83.9 | 399 | 80.1 |
Prevention and screening | 20 | 2.7 | 6 | 2.4 | 14 | 2.8 |
Diagnostic | 15 | 2.0 | 2 | 0.8 | 13 | 2.6 |
Supportive care | 29 | 3.9 | 12 | 4.7 | 17 | 3.4 |
Health services research | 5 | 0.7 | 1 | 0.4 | 4 | 0.8 |
Other | 34 | 4.5 | 4 | 1.6 | 30 | 6.0 |
Missing | 37 | 5.0 | 16 | 6.3 | 21 | 4.2 |
Endpoint classification | ||||||
Efficacy | 168 | 22.3 | 67 | 26.4 | 101 | 20.3 |
Safety | 80 | 10.6 | 27 | 10.6 | 53 | 10.6 |
Safety and efficacy | 256 | 34.0 | 68 | 26.8 | 188 | 37.8 |
Other | 106 | 14.1 | 18 | 7.1 | 88 | 17.7 |
Missing | 142 | 19.0 | 74 | 29.1 | 68 | 13.7 |
Sponsor | ||||||
Not-for-profit | 463 | 61.6 | 189 | 74.4 | 274 | 55.0 |
Profit | 289 | 38.4 | 65 | 25.6 | 224 | 45.0 |
Study duration (years) | ||||||
Mean (SD) | 4.48 (2.8) | 4.12 (2.9) | 4.64 (2.7) | |||
Range | 1–24 | 1–24 | 1–21 | |||
Number of subjects | ||||||
< 50 | 382 | 51.6 | 142 | 37.2 | 240 | 62.8 |
≥ 50 | 359 | 48.5 | 105 | 29.3 | 254 | 70.8 |